A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

Claiming Science magazine's breakthrough of the year in 2023 , these drugs are an absolute revelation: they give you ...

There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

What happened with Novo Nordisk stock? On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of ...

These drugs, called glucagon-like peptide-1 receptor agonists (GLP-1 RAs), work in several different ways to help people lose ...

Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

Ozempic has fast become a household name. In addition to helping people with diabetes manage their blood sugar levels, this ...

Semaglutide biosimilar is under clinical development by Leto Laboratories and currently in Phase II for Diabetes.

McKinsey & Company’s 2024 Future of Wellness study – which surveyed more than 5,000 consumers across the United States, Britain and China – found that 82 per cent of U.S. respondents consider wellness ...

Discover the inspiring weight loss journey of a dietitian who overcame PCOS and pregnancy challenges to achieve lasting ...